Pharmaceuticals company Sanofi has appointed former Roche scientist John Reed to head group research group as it makes a late entry into the immunotherapy cancer drug market . Dmitri Wiederschain , director of immuno - oncology research at the French drugmaker , believes the company could gain an advantage in the next wave of treatments that allow drugs to better target cancer , citing immunotherapies PD-1 , TGFBeta and the drug CD38 . Immunotherapy drug sales are forecast to reach $ 25bn a year by 2021 , according to Thomson Reuters analysis . However , Sanofi is unlikely to rival competitors like Roche and Merck , said Frederic comes from Sycomore Asset plc .
Pharmaceuticals company Sanofi has appointed former Roche scientist John Reed to head group research operations as it makes a late entry into the immunotherapy cancer drug market. Dmitri Wiederschain, head of immuno-oncology research at the French drugmaker, said the company could gain an advantage in the next wave of treatments that combine drugs to better target cancer, citing immunotherapies PD-1, TGFBeta and the antibody CD38. Immunotherapy drug sales are forecast to reach $25bn a year by 2021, according to Thomson Reuters analysis. However, Sanofi is unlikely to rival competitors like Roche and Merck, said Frederic Ponchon from Sycomore Asset Management.